We are live on ! Find out more
ARRY

Array Biopharma Inc
ARRY

Delisted

ARRY was delisted on the 29th of July, 2019.

187 hedge funds and large institutions have $1.49B invested in Array Biopharma Inc in 2017 Q1 according to their latest regulatory filings, with 48 funds opening new positions, 62 increasing their positions, 61 reducing their positions, and 21 closing their positions.

New
Increased
Maintained
Reduced
Closed

129% more first-time investments, than exits

New positions opened: 48 | Existing positions closed: 21

12% more funds holding

Funds holding: 167187 (+20)

6% more capital invested

Capital invested by funds: $1.41B → $1.49B (+$82.4M)

10% more call options, than puts

Call options by funds: $30.6M | Put options by funds: $27.9M

2% more repeat investments, than reductions

Existing positions increased: 62 | Existing positions reduced: 61

33% less funds holding in top 10

Funds holding in top 10: 64 (-2)

Holders
187
Holders Change
+20
Holders Change %
+11.98%
% of All Funds
4.66%
Holding in Top 10
4
Holding in Top 10 Change
-2
Holding in Top 10 Change %
-33.33%
% of All Funds
0.1%
New
48
Increased
62
Reduced
61
Closed
21
Calls
$30.6M
Puts
$27.9M
Net Calls
+$2.74M
Net Calls Change
-$2.54M
Name Holding Trade Value Shares
Change
Change in
Stake
CEP
51
Chicago Equity Partners
Illinois
$3.7M -$1.27M -119,470 -22%
CCI
52
Columbus Circle Investors
$3.44M -$1.55M -146,107 -28%
Wells Fargo
53
Wells Fargo
California
$3.35M -$17K -1,601 -0.4%
GAMA
54
Graticule Asia Macro Advisors
New York
$3.22M -$50K -4,700 -1%
RPAM
55
Rhenman & Partners Asset Management
Sweden
$3.13M -$2.13M -200,000 -36%
CM
56
Castleark Management
Illinois
$3.13M +$3.72M +349,781 New
Morgan Stanley
57
Morgan Stanley
New York
$3.12M -$28.9M -2,719,661 -89%
SIM
58
Spark Investment Management
New York
$3.07M +$864K +81,200 +31%
Citigroup
59
Citigroup
New York
$2.95M -$3.13M -294,354 -47%
Macquarie Group
60
Macquarie Group
Australia
$2.95M
California State Teachers Retirement System (CalSTRS)
61
California State Teachers Retirement System (CalSTRS)
California
$2.95M -$165K -15,500 -4%
AllianceBernstein
62
AllianceBernstein
Tennessee
$2.91M +$1.06M +99,850 +44%
AQR Capital Management
63
AQR Capital Management
Connecticut
$2.84M +$1.99M +186,678 +142%
ARTA
64
A.R.T. Advisors
New York
$2.8M +$2.8M +262,852 +526%
Wellington Management Group
65
Wellington Management Group
Massachusetts
$2.55M +$3.04M +285,638 New
Bank of America
66
Bank of America
North Carolina
$2.55M +$2.64M +247,672 +664%
State of New Jersey Common Pension Fund D
67
State of New Jersey Common Pension Fund D
New Jersey
$2.37M
GC
68
Guggenheim Capital
Illinois
$2.28M -$136K -12,737 -5%
California Public Employees Retirement System
69
California Public Employees Retirement System
California
$2.28M +$101K +9,500 +4%
Swiss National Bank
70
Swiss National Bank
Switzerland
$2.23M +$87.2K +8,200 +3%
Group One Trading
71
Group One Trading
Illinois
$2.19M +$2.61M +245,563 New
HI
72
HBK Investments
Texas
$2.06M +$2.45M +230,700 New
PVI
73
Pura Vida Investments
New York
$1.99M +$698K +65,640 +42%
RhumbLine Advisers
74
RhumbLine Advisers
Massachusetts
$1.91M +$122K +11,500 +6%
OAM
75
Oxford Asset Management
United Kingdom
$1.82M +$2.17M +203,630 New

ARRY Hedge Fund Activity: Q1 2017 in Review

187 of the 4,017 institutional investors tracked by Wall St. Rank reported a position in Array Biopharma Inc (ARRY) for Q1 2017, worth a combined $1.49B — up 5.9% from $1.41B a quarter earlier.

Buyers outnumbered sellers: 48 funds opened new ARRY positions and 21 closed out — a net gain of 27 holders — while 62 added to existing stakes and 61 trimmed.

The largest buyer was BlackRock, adding an estimated $137M. The largest seller was Redmile Group, cutting an estimated $41M.

  • 187 institutional investors held Array Biopharma Inc (ARRY) as of Q1 2017, up from 167 in Q4 2016.
  • Funds reported $1.49B of Array Biopharma Inc stock for Q1 2017, up 5.9% quarter-over-quarter.
  • 48 funds opened new Array Biopharma Inc positions in Q1 2017 and 21 closed out, a net change of +27 holders.
  • The largest Array Biopharma Inc buyer in Q1 2017 was BlackRock, an estimated $137M added.
  • The largest Array Biopharma Inc seller in Q1 2017 was Redmile Group, an estimated $41M sold.

Based on aggregated 13F filings for Q1 2017.